# US 8,541,367 B2 · Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,367 B2
- Document ID: US8541367B2
- Status: Granted
- Kind: B2
- Application number: 12/722,575
- Filed: 2010-03-12
- Published: 2010-09-16
- Granted: 2013-09-24
- Earliest claimed: 2009-03-12
- Assignees: Landing Biotech, Inc.
- Applicants: Jian-ning Liu
- Inventors: Jian-ning Liu
- Web page: https://patentgrep.com/patent/US8541367B2

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- G01N 33/5088: {of vertebrates}
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.

## Claims

### Claim 1

A method of lowering blood glucose in a subject having diabetes comprising the step of administering to said subject a composition comprising an effective amount of an insulin helper pladin (plasma anti-diabetic nucb2 peptide) consisting of the amino acid sequence of SEQ ID NO: 23.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered intravenously, subcutaneously, or orally.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pladin has a mutation at Arg13 or Lys28.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pladin is conjugated with one or more molecules to increase its molecular weight.

### Claim 5 (depends on 4)

The method of claim 4, wherein the conjugated molecule reduces blood glucose without penetration of blood-brain barrier.

### Claim 6 (depends on 1)

The method of claim 1, wherein when the subject is having type 2 diabetes, the method further comprises the step of administering insulin to the subject.

### Claim 7

A recombinant pladin (plasma anti-diabetic nucb2 peptide) consisting of the amino acid sequence of SEQ ID NO: 23.

### Claim 8

A recombinant pladin (plasma anti-diabetic nucb2 peptide) consisting of the amino acid sequence of SEQ ID NO: 23, wherein the pladin has a mutation at Arg13 or Lys28.

### Claim 9 (depends on 1)

A composition comprising the pladin of claim 1.